Designing novel drugs that target RANKL RANK and their signaling pathways in osteoclasts could potentially revolutionize the treatment of many diseases associated with bone loss such as arthritis, tooth loss, cancer metastases or osteoporosis.
These data suggest that targeting cathepsin K may prove therapeutically beneficial in the treatment of diseases with accelerated bone loss such as postmenopausal osteoporosis not only by inhibiting bone resorption but also by potentially stimulating cortical bone formation.
Therefore, laboratory assessment should be prescribed to investigate the main cause of bone loss, such as hyperthyroidism, hypercortisolism, multiple myeloma, or celiac disease.
Children admitted to pediatric intensive care units (PICU) are also exposed to many potential risk factors for bone loss such as immobilization, catabolic state, and nutritional depletion.
Among them: immobilization (due to neurologic condition, sedation, or paralysis), catabolic state and endocrine imbalance, nutritional depletion, sun deprivation, and at times, use of medications that promote bone loss such as steroids, antiepileptic drugs [17], diuretics [18], or heparin [19].
TNF-α enhancement by IL-7 is also present in other pathological conditions, characterized by a local and/or systemic bone loss, such as rheumatoid arthritis [30] or postmenopausal osteoporosis [38].
This observation may reveal the role of common determinants of both breast density and bone mineral density/height loss, such as changes in oestrogen levels.
The skeleton is the major endogenous source of lead in circulating blood, particularly under conditions of accelerated bone turnover and mineral loss, such as during pregnancy and in postmenopausal osteoporosis.
The ability of human body to regenerate tissue loss such as bone, cartilage, nerves, skin and muscle is limited leading often to amputations of limbs or functional disability.
Subjects were classified as having gingivitis (only) if they did not demonstrate any sign of attachment loss, such as pockets, gingival recession and bone loss.
In SpA (especially AS), other potential risk factors for bone loss occur, such as inflammation and mechanical factors: rigidity of the spine resulting in limited mobility and reduced physical activity due to pain and stiffness.
